(273 days)
Not Found
Not Found
No
The description focuses on standard defibrillator and pacemaker functions, with no mention of AI or ML technologies. The advisory function appears to be based on pre-defined criteria (ventricular fibrillation and tachycardia > 150 bpm) rather than adaptive learning.
Yes
The device is indicated for converting ventricular fibrillation and rapid ventricular tachycardia to sinus rhythm, and for cardiac pacing, all of which are therapeutic interventions aimed at treating a medical condition or restoring normal function.
Yes
The device has an "Advisory Function" which is used to "confirm ventricular fibrillation and ventricular tachycardia". This function provides information about a patient's condition, which aligns with the definition of a diagnostic device.
No
The device description explicitly states it "contains a standard DC defibrillator capable of delivering up to 360 joules of energy," indicating it is a hardware device with a physical component for delivering electrical shocks.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze samples taken from the human body. The intended use and device description clearly indicate that the ZOLL REVIVER is used on the patient's body (applying electrical shocks for defibrillation and pacing) and analyzes the patient's ECG directly. It does not analyze blood, urine, tissue, or other samples taken from the patient.
- The functions described are therapeutic and diagnostic in vivo. Defibrillation and pacing are therapeutic interventions. The advisory function and ECG analysis are diagnostic, but they are performed on the living patient, not on a sample in a lab setting.
The device is a medical device, specifically a defibrillator and pacemaker, but it does not fit the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Defibrillator Function
Indications for Use - Manual Operation
Use of the ZOLL REVIVER in the manual mode for defibrillation is indicated on victims of cardiac arrest where there is apparent lack of circulation as indicated by:
- Unconsciousness
- Absence of breathing .
- Absence of pulse.
The ZOLL REVIVER contains a standard DC defibrillator capable of delivering up to 360 joules of energy. In manual mode, it may also be used for synchronized cardioversion by using the R-wave of the patient's ECG as a timing reference.
This product is to be used only by qualified medical personnel for the purposes of converting ventricular fibrillation and rapid ventricular tachycardia to sinus rhythm or other cardiac rhythms capable of producing hemodynamically significant heart beats.
Indications for Use - Advisory Function
The advisory function should only be used to confirm ventricular fibrillation and ventricular tachycardia (greater than 150 beats per minute) in patients meeting the following clinical criteria:
- · Unconsciousness
- Absence of breathing
- Absence of pulse.
Indications for Use - Semiautomatic Operation (if equipped)
The ZOLL REVIVER is designed for use by emergency care personnel who have completed training and certification requirements applicable to the use of a defibrillator where the operator of the device controls the delivery of the shock to the patient. It is specifically designed for use in early defibrillation programs where the delivery of a defibrillator shock during resuscitation involving CPR, transportation, and definitive care are incorporated in a medically-approved patient care protocol.
The ZOLL REVIVER must be prescribed for use by a physician or medical advisor of an emergency response team.
Use of the ZOLL REVIVER in the semiautomatic mode for defibrillation is indicated on victims of cardiac arrest where there is apparent lack of circulation as indicated by:
- . Unconsciousness
- . Absence of breathing
- Absence of pulse. .
Pacemaker Function (if equipped)
Indications for Use - Pacemaker
This product may be used for cardiac pacing in conscious patients for up to a few hours duration as an alternative to endocardial stimulation. The purposes of pacing include:
1 Resuscitation from standstill or bradycardia of any etiology:
Noninvasive pacing has been used for resuscitation from cardiac standstill, reflex vagal standstill, drug induced standstill (due to procainamide, quinidine, digitalis, ß-blockers, verapamil, etc.) and unexpected circulatory arrest (due to anesthesia, surgery, angiography, and other therapeutic or diagnostic procedures). It has also been used for temporary acceleration of bradycardia in Stokes-Adams disease and sick-sinus syndrome. It is safer, more reliable, and more rapidly applied in an emergency than endocardial or other temporary electrodes.
2 As a standby when standstill or bradycardia might be expected:
Noninvasive pacing may be useful as a standby when cardiac arrest or symptomatic bradycardia might be expected due to acute myocardial infarction, drug toxicity, anesthesia or surgery. It is also useful as a temporary treatment in patients awaiting pacemaker implants or the introduction of transvenous therapy. In standby pacing applications, noninvasive pacing may provide an alternative to transvenous therapy which avoids the risks of displacement, infection, hemorrhage, embolization, perforation, phlebitis and mechanical or electrical stimulation of ventricular tachycardia or fibrillation associated with endocardial pacing.
3 Suppression of tachycardia:
An increase in heart rate from external pacing offen suppresses ventricular ectopic activity and may prevent tachycardia.
Product codes
74 MKJ
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
qualified medical personnel, emergency care personnel, physician or medical advisor of an emergency response team.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.5310 Automated external defibrillator system.
(a)
Identification. An automated external defibrillator (AED) system consists of an AED and those accessories necessary for the AED to detect and interpret an electrocardiogram and deliver an electrical shock (e.g., battery, pad electrode, adapter, and hardware key for pediatric use). An AED system analyzes the patient's electrocardiogram, interprets the cardiac rhythm, and automatically delivers an electrical shock (fully automated AED), or advises the user to deliver the shock (semi-automated or shock advisory AED) to treat ventricular fibrillation or pulseless ventricular tachycardia.(b)
Classification. Class III (premarket approval)(c)
Date PMA or notice of completion of PDP is required. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED that was in commercial distribution before May 28, 1976. A PMA will be required to be submitted to the Food and Drug Administration by April 29, 2015, for any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976, or that has, by April 29, 2015, been found to be substantially equivalent to any AED accessory described in paragraph (a) that was in commercial distribution before May 28, 1976. Any other AED and AED accessory described in paragraph (a), shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
0
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a stylized eagle with three swooping lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
MAR 1 6 1998
Ms. Maura McGuire Quality Assurance Manager Zoll Medical Corporation 32 Second Avenue Burlington, MA 01803-4420
K972241 Re: Zoll Reviver Regulatory Class: III (three) Product Code: 74 MKJ December 12, 1997 Dated: December 16, 1997 Received:
Dear Ms. McGuire:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Druq, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, qood manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 A substantially equivalent determination assumes compliance to 895. with the current Good Manufacturing-Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices . . . . . . . . General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
1
Page 2 - Ms. Maura McGuire
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your dev`ice to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4648. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Please be advised that, in the future, FDA may require postmarket surveillance of this device under the authorities granted under section 522 of the Federal Food, Drug and Cosmetic Act. This issue is currently under consideration by FDA and you will be notified of our decision in writing.
Sincerely yours,
Thomas J. Callahan
Thomas J. Callahan, Ph.D. Director Division of Cardiovascular, Respiratory, and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Page 1 of 2
510(k) Number (if known):
Device Name:__________________________________________________________________________________________________________________________________________________________________
Indications For Use:
Defibrillator Function
Indications for Use - Manual Operation
Use of the ZOLL REVIVER in the manual mode for defibrillation is indicated on victims of cardiac arrest where there is apparent lack of circulation as indicated by:
- Unconsciousness
- Absence of breathing .
- Absence of pulse.
The ZOLL REVIVER contains a standard DC defibrillator capable of delivering up to 360 joules of energy. In manual mode, it may also be used for synchronized cardioversion by using the R-wave of the patient's ECG as a timing reference.
This product is to be used only by qualified medical personnel for the purposes of converting ventricular fibrillation and rapid ventricular tachycardia to sinus rhythm or other cardiac rhythms capable of producing hemodynamically significant heart beats.
Indications for Use - Advisory Function
The advisory function should only be used to confirm ventricular fibrillation and ventricular tachycardia (greater than 150 beats per minute) in patients meeting the following clinical criteria:
- · Unconsciousness
- Absence of breathing
- Absence of pulse.
(continued on next page)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Willy Severson mb
(Division Sign-Off) Division of Cardiovascular, Respiratory, and Neurological Devices 510(k) Number
Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use
(Optional Format 1-2-96)
3
Indications For Use (continued from previous page)
Indications for Use - Semiautomatic Operation (if equipped)
The ZOLL REVIVER is designed for use by emergency care personnel who have completed training and certification requirements applicable to the use of a defibrillator where the operator of the device controls the delivery of the shock to the patient. It is specifically designed for use in early defibrillation programs where the delivery of a defibrillator shock during resuscitation involving CPR, transportation, and definitive care are incorporated in a medically-approved patient care protocol.
The ZOLL REVIVER must be prescribed for use by a physician or medical advisor of an emergency response team.
Use of the ZOLL REVIVER in the semiautomatic mode for defibrillation is indicated on victims of cardiac arrest where there is apparent lack of circulation as indicated by:
- . Unconsciousness
- . Absence of breathing
- Absence of pulse. .
Pacemaker Function (if equipped)
Indications for Use - Pacemaker
This product may be used for cardiac pacing in conscious patients for up to a few hours duration as an alternative to endocardial stimulation. The purposes of pacing include:
1 Resuscitation from standstill or bradycardia of any etiology:
Noninvasive pacing has been used for resuscitation from cardiac standstill, reflex vagal standstill, drug induced standstill (due to procainamide, quinidine, digitalis, ß-blockers, verapamil, etc.) and unexpected circulatory arrest (due to anesthesia, surgery, angiography, and other therapeutic or diagnostic procedures). It has also been used for temporary acceleration of bradycardia in Stokes-Adams disease and sick-sinus syndrome. It is safer, more reliable, and more rapidly applied in an emergency than endocardial or other temporary electrodes.
2 As a standby when standstill or bradycardia might be expected:
Noninvasive pacing may be useful as a standby when cardiac arrest or symptomatic bradycardia might be expected due to acute myocardial infarction, drug toxicity, anesthesia or surgery. It is also useful as a temporary treatment in patients awaiting pacemaker implants or the introduction of transvenous therapy. In standby pacing applications, noninvasive pacing may provide an alternative to transvenous therapy which avoids the risks of displacement, infection, hemorrhage, embolization, perforation, phlebitis and mechanical or electrical stimulation of ventricular tachycardia or fibrillation associated with endocardial pacing.
3 Suppression of tachycardia:
An increase in heart rate from external pacing offen suppresses ventricular ectopic activity and may prevent tachycardia.